JP2018535224A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535224A5
JP2018535224A5 JP2018526543A JP2018526543A JP2018535224A5 JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5 JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nanoparticle
composition according
patient
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535224A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/062816 external-priority patent/WO2017087825A1/en
Publication of JP2018535224A publication Critical patent/JP2018535224A/ja
Publication of JP2018535224A5 publication Critical patent/JP2018535224A5/ja
Pending legal-status Critical Current

Links

JP2018526543A 2015-11-19 2016-11-18 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤 Pending JP2018535224A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257569P 2015-11-19 2015-11-19
US62/257,569 2015-11-19
PCT/US2016/062816 WO2017087825A1 (en) 2015-11-19 2016-11-18 Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations

Publications (2)

Publication Number Publication Date
JP2018535224A JP2018535224A (ja) 2018-11-29
JP2018535224A5 true JP2018535224A5 (enExample) 2019-12-26

Family

ID=58717907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526543A Pending JP2018535224A (ja) 2015-11-19 2016-11-18 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤

Country Status (12)

Country Link
US (1) US20180339024A1 (enExample)
EP (1) EP3377080B1 (enExample)
JP (1) JP2018535224A (enExample)
KR (1) KR20180081608A (enExample)
CN (1) CN108883150A (enExample)
AU (1) AU2016358125A1 (enExample)
BR (1) BR112018010052A2 (enExample)
CA (1) CA3005284A1 (enExample)
IL (1) IL259376A (enExample)
MX (1) MX2018006194A (enExample)
SG (2) SG10202004259PA (enExample)
WO (1) WO2017087825A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118717953A (zh) 2017-04-06 2024-10-01 莎思坦控股有限责任公司 基于胶原的药物组合物和装置和生产方法及其用途
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
US20210113654A1 (en) * 2018-05-31 2021-04-22 Yale University Methods and Compositions to Alleviate Vascular Permeability
US12540171B2 (en) 2019-03-26 2026-02-03 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP4552693A3 (en) 2019-04-22 2025-06-11 Sustain Holdings, LLC Collagen peptide-based medicament compositions and devices and methods of production and use thereof
US20230086800A1 (en) * 2020-03-06 2023-03-23 The Board Of Trustees Of The Leland Stanford Junior University Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0773952B1 (en) 1994-07-20 2003-11-12 The General Hospital Corporation Interaction trap systems for detecting protein interactions
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2372464C (en) 1999-05-05 2012-07-31 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
ATE488584T1 (de) 1999-05-26 2010-12-15 Next Biomed Technologies Nbt Oy Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP2284270A3 (en) 2000-12-13 2012-07-25 Anaphore, Inc. Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
BR0212256A (pt) 2001-08-30 2004-08-31 Biorexis Pharmaceutical Corp Proteìnas de fusão de transferrina modificadas
MXPA05003493A (es) 2002-10-02 2005-09-30 Catalyst Biosciences Metodos para generar y seleccionar proteasas con especificidad alterada.
JP2007524348A (ja) 2003-01-07 2007-08-30 ダイアックス、コープ クニッツドメインライブラリー
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
WO2008085828A2 (en) * 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
US8992991B2 (en) * 2009-05-15 2015-03-31 The Johns Hopkins University Multicomponent degradable cationic polymers
WO2011084509A1 (en) * 2009-12-15 2011-07-14 Massachusetts Institute Of Technology Endothelial basement membrane targeting peptide ligands
WO2012079088A2 (en) 2010-12-10 2012-06-14 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
US9309286B2 (en) * 2011-08-17 2016-04-12 Tufts Medical Center Compositions and methods for augmenting permeability barriers
WO2013086500A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
WO2014018018A1 (en) * 2012-07-24 2014-01-30 Morehouse School Of Medicine Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN105431162B (zh) 2013-06-07 2019-12-10 约翰霍普金斯大学 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
PT3052192T (pt) * 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações

Similar Documents

Publication Publication Date Title
Yasmin et al. Novel drug delivery systems for inflammatory bowel disease
Du et al. Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation
Khan et al. PLGA nanoparticles and their versatile role in anticancer drug delivery
Wu et al. Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases
Hu et al. Tumor microenvironment-mediated construction and deconstruction of extracellular drug-delivery depots
Cabeza et al. Nanoparticles in colorectal cancer therapy: latest in vivo assays, clinical trials, and patents
CN109890420B (zh) 用于递送治疗剂的血小板组合物和方法
Liu et al. Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage
JP6343147B2 (ja) 狭窄病変および血栓溶解療法のための剪断による制御放出
US20170333365A1 (en) Core-shell particle formulation for delivering multiple therapeutic agents
Pinto et al. Targeted brain delivery nanoparticles for malignant gliomas
JP2016521712A5 (enExample)
CN102970864A (zh) 纳米颗粒药物组合物
Guo et al. Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy
Morales-Orue et al. Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies
Zhao et al. Teaching new tricks to old dogs: A review of drug repositioning of disulfiram for cancer nanomedicine
Mishra et al. Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles
CA3005284A1 (en) Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
Panchangam et al. Engineered nanoparticles for the delivery of anticancer therapeutics
Jeswani et al. Advances in the delivery of cancer therapeutics: a comprehensive review
Joshi et al. Inhibition of cancer cell metastasis by nanotherapeutics: current achievements and future trends
Su et al. Eudragit S100 coated nanodiamond-based nanoparticles as an oral chemo-photothermal delivery system for local treatment of colon cancer
Al-Amili et al. Self-assembled micelles of amphiphilic PEGylated drugs for cancer treatment
Yang et al. Intravenous administration of scutellarin nanoparticles augments the protective effect against cerebral ischemia–reperfusion injury in rats
Wei et al. Cell-and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy